BJC HealthCare

Belkins
BJC HealthCare is one of the largest nonprofit health care organizations in the United States, and is focused on delivering services to residents primarily in the greater St. Louis, southern Illinois and mid-Missouri regions. BJC HealthCare has ranked as one of the top workplaces among large employers in the seventh annual St. Louis Post-Dispatch Top Workplaces for 2018 program. BJC is one of 150 Greater St. Louis employers to receive the award and the only health care system to make the list.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PRACTICE MANAGEMENT

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN ORLADEYO AND BCX9930 FROM BIOCRYST PHARMACEUTICALS

Royalty Pharma | December 08, 2020

news image

Royalty Pharma, BioCryst Pharmaceuticals, Inc. what's more, Athyrium Capital Management, LP today declared exchanges adding up to $325 million in financing for BioCryst, with $250 million accessible at shutting, to help the dispatch of ORLADEYO™ (berotralstat) in genetic angioedema (HAE) and the advancement of its oral Factor D inhibitor, BCX9930. Royalty Pharma will furnish BioCryst with a forthright money installment of $125 million and will get eminences of 8.75% on d...

Read More

POLICY AND REGULATION

EPIENDO PHARMACEUTICALS SECURES FUNDING TO ADVANCE CLINICAL DEVELOPMENT OF ITS NON-ANTIBIOTIC MACROLIDE FOR THE TREATMENT OF COPD

EpiEndo Pharmaceuticals | August 19, 2021

news image

EpiEndo Pharmaceuticals , a privately held biopharmaceutical company focused on a novel barrier enhancing approach to the treatment of chronic inflammatory airway diseases such as chronic obstructive pulmonary disease (COPD), announces the closing of a €20m Series A financing round led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council (EIC) Fund joining the round. The financing secures funds to advance...

Read More

RESEARCH

REGENERON, FOLLOWING IN LILLY'S FOOTSTEPS, WINS FDA EMERGENCY NOD FOR COVID-19 ANTIBODY COCKTAIL

Regeneron | November 24, 2020

news image

Covid-19 Regeneron antibody cocktail, one of the drugs of President Donald Trump was given after he was infected with the SARS-COV-02 virus, had been cleaned for emergency use by the FDA. And, despite the towering vaccine slide, one analyst still sees therapy as a $ 1 billion-plus business. Authorization of Emergency Use (EUA) for Regn-COV2, a combination of monoclonal antibodies Kasarivimab and IMdevimab, marked the second for antibody therapy. The first to go to Bamlanivimab Eli...

Read More

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

news image

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More

PRACTICE MANAGEMENT

Royalty Pharma | December 08, 2020

news image

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN ORLADEYO AND BCX9930 FROM BIOCRYST PHARMACEUTICALS

Royalty Pharma, BioCryst Pharmaceuticals, Inc. what's more, Athyrium Capital Management, LP today declared exchanges adding up to $325 million in financing for BioCryst, with $250 million accessible at shutting, to help the dispatch of ORLADEYO™ (berotralstat) in genetic angioedema (HAE) and the advancement of its oral Factor D inhibitor, BCX9930. Royalty Pharma will furnish BioCryst with a forthright money installment of $125 million and will get eminences of 8.75% on d...

Read More

POLICY AND REGULATION

EpiEndo Pharmaceuticals | August 19, 2021

news image

EPIENDO PHARMACEUTICALS SECURES FUNDING TO ADVANCE CLINICAL DEVELOPMENT OF ITS NON-ANTIBIOTIC MACROLIDE FOR THE TREATMENT OF COPD

EpiEndo Pharmaceuticals , a privately held biopharmaceutical company focused on a novel barrier enhancing approach to the treatment of chronic inflammatory airway diseases such as chronic obstructive pulmonary disease (COPD), announces the closing of a €20m Series A financing round led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council (EIC) Fund joining the round. The financing secures funds to advance...

Read More

RESEARCH

Regeneron | November 24, 2020

news image

REGENERON, FOLLOWING IN LILLY'S FOOTSTEPS, WINS FDA EMERGENCY NOD FOR COVID-19 ANTIBODY COCKTAIL

Covid-19 Regeneron antibody cocktail, one of the drugs of President Donald Trump was given after he was infected with the SARS-COV-02 virus, had been cleaned for emergency use by the FDA. And, despite the towering vaccine slide, one analyst still sees therapy as a $ 1 billion-plus business. Authorization of Emergency Use (EUA) for Regn-COV2, a combination of monoclonal antibodies Kasarivimab and IMdevimab, marked the second for antibody therapy. The first to go to Bamlanivimab Eli...

Read More

BioSpace | March 02, 2020

news image

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More